India’s pharmaceutical exports reached a record $30.47 billion in FY25, exceeding the $29.38 billion target.
This marked a 9.39% increase over FY24, with a 31.21% year-on-year surge in March 2025 alone, the highest monthly growth.
March exports stood at $3.68 billion, followed by strong performance in January and May; February was the only month showing a decline.
Growth came despite challenges like geopolitical tensions, economic slowdown, and logistical issues.
Drug formulations and biologicals were the largest export category, contributing over 75% of the total with nearly 9% growth.
Bulk drugs and intermediates rose 1.4%, while vaccine exports fell 4.2%. Ayush, herbal products, and surgicals saw moderate growth.
The U.S. remained India’s top pharma export market, accounting for over a third of total exports and showing 14.29% growth.
Other key markets included the U.K., Brazil, France, and South Africa, though some like UAE, Turkey, and China saw declines.
Regionally, NAFTA, Europe, Africa, and LAC accounted for 76% of total exports, with NAFTA alone contributing 36.6% and growing 14%.
Exports to Africa and North East Asia declined, reflecting mixed trends across global markets.
COMMENTS